Technology | Artificial Intelligence | June 20, 2019

TeraRecon Receives First-of-Kind FDA Determination for Northstar AI Results Explorer

Class I medical device provides physicians way to accept, reject and interact with artificial intelligence-derived radiology findings

TeraRecon Receives FDA Clearance for Northstar AI Results Explorer

June 20, 2019 — Advanced visualization and artificial intelligence (AI) technology provider TeraRecon has successfully completed a U.S. Food and Drug Administration (FDA) regulatory review of its Northstar AI Results Explorer. TeraRecon said the technology and the determination are both firsts-of-kind in the medical imaging industry. Northstar is designed to work alongside the company’s EnvoyAI interoperability platform, which includes FDA-cleared third-party content listed on its EnvoyAI Exchange marketplace.

The Northstar AI Results Explorer provides an engaging physician user experience that can be integrated into the clinical systems already used throughout the health enterprise. Now with full commercial availability, Northstar can provide physicians a way to accept, reject and interact with AI-derived findings. Through the EnvoyAI marketplace, health systems can enter into a single contractual agreement and confidently run algorithms interchangeably, with a single two-hour software installation.

EnvoyAI customers currently have access to more than 80 algorithms with 20 holding regulatory clearances in various global territories.

TeraRecon maintains stringent processes, documentation and quality systems across its design, development and business operations. The FDA has determined that the Northstar AI Results Explorer is exempt from Class II premarket notification requirements, and therefore is considered a Class I medical device alongside their existing Class I EnvoyAI platform.

TeraRecon technologies including the EnvoyAI platform, TeraRecon Northstar AI Results Explorer and its flagship iNtuition advanced visualization solution, will be on display at the Society for Imaging Informatics in Medicine (SIIM) conference, June 26-28 in Aurora, Colo.

For more information: www.terarecon.com

Related Content

Sponsored Content | Videos | Artificial Intelligence | February 21, 2020
In Artificial Intelligence at RSNA 2019, ITN Contributing Editor Greg Freiherr offers an overview of artificial intel
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Altamont’s zero-footprint solution, CaptureWare, allows Mach7’s Enterprise Imaging Platform (EIP) to ingest more DICOM and/or non-DICOM data from various sources in a facility
News | PACS | February 20, 2020
February 20, 2020 — Mach7 announced its partnership with Altamont
Sponsored Content | Videos | Enterprise Imaging | February 19, 2020
Bill Lacy, vice president, Medical Informatics at FUJIFILM Medic...
The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

News | Artificial Intelligence | February 13, 2020
February 13, 2020 — The U.S.
The Candelis ImageGrid Plus PACS Server is an ultra-high-performance platform that can support high volume healthcare environments of 1,000 plus modalities
News | PACS | February 12, 2020
February 12, 2020 — The Candelis ImageGrid Plus...
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...